InspireMD, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- InspireMD, Inc. develops and commercializes advanced medical devices focused on carotid artery disease and stroke prevention. Its main products include the CGuard® Prime carotid stent system featuring MicroNet technology designed to reduce embolic complications during carotid artery stenting; the SwitchGuard transcarotid system providing neuroprotection during transcarotid artery revascularization (TCAR); and related vascular intervention tools. The company serves vascular surgeons, interventional cardiologists, and hospitals, operating primarily in the United States, Europe, and over 30 international markets. Founded in 2005 and headquartered in Miami, Florida, InspireMD maintains a specialized focus within the healthcare supplies segment. Recently, InspireMD has executed its U.S. commercial launch of the CGuard Prime carotid stent system following FDA approval received in June 2025, marking a significant milestone in its strategic expansion. The company secured $58 million in combined financings in mid-2025 to fund expanded commercial activities and research and development. It appointed Peter A. Soukas, M.D., as Chief Medical Officer to enhance its clinical and medical strategy. InspireMD also achieved expanded U.S. reimbursement coverage, grew revenue by 39% year-over-year in Q3 2025 with increased sales both domestically and internationally, and advanced its product pipeline with ongoing clinical trials for broader indications including acute stroke. Partnerships with Chinese investment firms such as Shanghai Micro Medical support global registration efforts, underpinning InspireMD’s growth and innovation in the carotid intervention market. These developments collectively position InspireMD as a key player advancing neuroprotection and stroke prevention technologies globally.
InspireMD Posts Positive CGUARDIANS II Data for CGuard Prime TCAR
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures
InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
InspireMD, Inc. (NSPR) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference
InspireMD, Inc. (NSPR) Reports Q1 Loss, Tops Revenue Estimates
InspireMD, Inc. (NSPR) Q1 2026 Earnings Call Transcript
InspireMD Reports First Quarter 2026 Financial Results
InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System
InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System
InspireMD to Announce First Quarter 2026 Financial Results
InspireMD to Announce First Quarter 2026 Financial Results
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of InspireMD, Inc. (NASDAQ: NSPR)
After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR)
InspireMD (NYSE:NSPR) Trading Down 6.7% – What’s Next?
InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference
InspireMD, Inc. (NSPR) Q4 2025 Earnings Call Transcript
InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates
InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results